drugset / Trial / NCT05349409
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate safety, tolerability and preliminary efficacy of SHR-A1811 for Injection in combination with Fluzoparib Capsule for HER2-expressing advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for HER2-expressing advanced malignant tumors of patients.
Timeline
- Start
- 2022-06-09
- Primary completion
- 2024-11-30
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | — | Oral |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | Intravenous |